Admelog is highly similar to Humalog in it's safety, effectiveness, and dosing. As a follow-on insulin, Admelog will provide a more affordable option to Humalog

Both Admelog and Humalog are insulin lispro injections used to control blood sugar (glucose) in patients 3 years and older with type 1 diabetes and adults with type 2 diabetes. Humalog, from Eli Lilly, is the original reference product and Admelog, from Sanofi, is the first rapid-acting, mealtime insulin approved as a “follow-on” product that relied, in part, on the FDA’s finding of safety and effectiveness for Humalog to support approval (approved via 505(b)(2), an abbreviated pathway).

How does Admelog come?

Admelog (insulin lispro injection) is available in the U.S. as a 100 Unit/mL (U-100) multidose 10 mL vial and as the disposable, 3 mL SoloStar prefilled pen. Admelog can be administered by injection under the skin (subcutaneously), by continuous subcutaneous infusion (by pump), or by intravenous (IV) infusion after dilution. Admelog is used within 15 minutes before a meal or immediately after.